Drug Trial News

RSS

Existing epilepsy drug reverses aMCI in elderly patients at risk for Alzheimer's disease

A novel therapeutic approach for an existing drug reverses a condition in elderly patients who are at high risk for dementia due to Alzheimer's disease, researchers at Johns Hopkins University found.

12 Mar 2015

Fourth patient dosed in Benitec Biopharma's Phase I/IIa hepatitis C trial

Benitec Biopharma, a biopharmaceutical company focused on providing potentially curative therapies with its proprietary gene-silencing technology called ddRNAi or "expressed RNAi," today announced that the fourth patient in the company's Phase I/IIa dose escalation clinical trial of its lead program TT-034 for treating hepatitis C was dosed at the Duke Clinical Research Unit.

11 Mar 2015

Recruitment completed for Phase III PROUD-PV trial of P1101 for treatment of polycythemia vera

PharmaEssentia (Taipei, Taiwan) and AOP Orphan (Vienna, Austria) announce the completion of recruitment for the Phase III trial PROUD-PV to support global marketing of P1101 (Ropeginterferon alfa-2b), a novel, long-acting, mono-pegylated interferon for the first line treatment of polycythemia vera.

11 Mar 2015

Brain tumor experts launch revolutionary fast-track approach to cancer research

Brain tumor experts at Barrow Neurological Institute at Dignity Health St. Joseph's Hospital and Medical Center have launched a revolutionary fast-track approach to cancer research, giving new hope to brain cancer patients.

10 Mar 2015

Chemotherapy, radiation therapy combination improves outcomes for people with low-grade brain cancer

New clinical-trial findings provide further evidence that combining chemotherapy with radiation therapy is the best treatment for people with a low-grade form of brain cancer. The findings come from a phase II study co-led by a researcher at Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute and researchers at the University of Maryland and at London Regional Cancer Program in Ontario, Canada.

10 Mar 2015

Advanced Cell Diagnostics' RNAscope technology supports biomarker-selected phase 2 clinical trial of Merrimack Pharmaceuticals' MM-121

Advanced Cell Diagnostics, Inc. (ACD) announced today that Merrimack Pharmaceuticals, Inc. is using ACD's RNAscope technology to select patients for its Phase 2 clinical trial of its product candidate MM-121.

From Advanced Cell Diagnostics 9 Mar 2015

Pacritinib for myelofibrosis meets primary endpoint in Phase 3 PERSIST-1 trial

CTI BioPharma Corp. and Baxter International Inc. today announced positive top-line results for the primary endpoint from PERSIST-1, the randomized, controlled Phase 3 registration clinical trial examining pacritinib, a next generation oral JAK2/FLT3 multikinase inhibitor, for the treatment of patients with primary or secondary myelofibrosis.

From Baxter International Inc. 9 Mar 2015

Clinical study launched to evaluate effectiveness of new HCV therapy in Washington, D.C.

Officials from the National Institutes of Health and the city of Washington, D.C., launched a clinical trial to examine whether primary care physicians and other health care providers, such as nurse practitioners and physician assistants, can use a new antiviral therapy as effectively as specialist physicians to treat people with hepatitis C virus (HCV) infection.

9 Mar 2015

Phase 3 trial results show that new testosterone nasal gel is effective and practical

A new testosterone nasal gel raises men's low testosterone levels to normal, with few side effects, according to the results of a phase 3 clinical trial to be presented Saturday at the Endocrine Society's 97th annual meeting in San Diego.

9 Mar 2015

Sunitinib holds promise for treatment of advanced differentiated thyroid cancer

In patients with advanced thyroid cancer, sunitinib, a drug approved for treatment of several other cancers, showed significant cancer-fighting activity t, a new phase 2 clinical trial has found. Results of the single-center study will be presented Sunday at the Endocrine Society's 97th annual meeting in San Diego.

9 Mar 2015

$Investigational drug for postmenopausal osteoporosis reduces rate of new spinal fractures$

Investigational drug for postmenopausal osteoporosis reduces rate of new spinal fractures

Abaloparatide-SC, an injectable drug being studied for the treatment of postmenopausal osteoporosis, reduces the rate of new spinal fractures by a statistically significant 86 percent and as well as statistically significant reductions in the fracture rate at other parts of the body, a phase 3 clinical trial finds. Results of the ACTIVE fracture prevention trial will be described in a late-breaking oral presentation Thursday at the Endocrine Society's 97th annual meeting in San Diego.

9 Mar 2015

Liraglutide may help obese adults achieve weight loss

Obesity guidelines recommend an initial weight loss goal of 5 to 10% of start weight to improve health. A recent study found that patients who received liraglutide 3.0 mg, combined with fewer calories and more physical activity, were more than twice as likely to achieve at least that level of weight loss, compared to patients on placebo who made similar lifestyle changes.

7 Mar 2015

Pre-clinical data on Novogen’s Cantrixil to be presented at two upcoming conferences

Novogen today announces that Professor Gil Mor MD PhD from Yale Medical School will be presenting pre-clinical data on the lead candidate product, Cantrixil, at two upcoming conferences.

6 Mar 2015

Obesity drug under clinical trials could help treat anxiety

Did you know that our body produces its own marijuana-like compound to protect us against anxiety? A study led by Ottawa researchers, published today in Neuron, reveals a new biological pathway that regulates this system and suggests that a drug currently in clinical trials to treat obesity might also provide an attractive way to combat anxiety disorders.

6 Mar 2015

Asterias begins enrollment for AST-OPC1 Phase 1/2a trial to treat complete cervical spinal cord injury

Asterias Biotherapeutics, Inc., a leading biotechnology company in the emerging field of regenerative medicine, announced today that Atlanta-based Shepherd Center, one of the nation's top rehabilitation hospitals for spinal cord injury and brain injury, has commenced enrollment for the Phase 1/2a clinical trial of AST-OPC1 (oligodendrocyte progenitor cells) in newly injured patients with sensory and motor complete cervical spinal cord injury (SCI).

5 Mar 2015

Phase III trial to test VSV-EBOV vaccine for preventing Ebola to be launched in Guinea

Based on promising data from initial clinical trials in late 2014, WHO with the Health Ministry of Guinea, Médecins Sans Frontières, Epicentre and The Norwegian Institute of Public Health, will launch a Phase III trial in Guinea on 7 March to test the VSV-EBOV vaccine for efficacy and effectiveness to prevent Ebola.

5 Mar 2015

Adding goserelin drug to chemotherapy prevents early menopause in young women with breast cancer

Early menopause can be prevented and fertility may be preserved in young women with early stage breast cancer, according to a study published today in The New England Journal of Medicine

5 Mar 2015

Symbiomix Therapeutics announces positive results from SYM-1219 Phase 1 clinical program

Symbiomix Therapeutics, a late-stage, privately held biopharmaceutical company developing innovative medicines for serious women's health infections, today announced results from its Phase 1 clinical program demonstrating that its lead product candidate, SYM-1219, was safe and well tolerated and had predictable pharmacokinetics (PK), and that contraceptive efficacy for birth control pills would not be altered by SYM-1219 administration.

4 Mar 2015

Resverlogix, Emerald Logic complete collaborative research program

Resverlogix Corp. today announced that it has completed a collaborative research program with Emerald Logic, a leader in quantitative analytics. Using Fast Collective Evolution Technology (FACET), Emerald Logic analyzed Resverlogix's complete clinical dataset including all measurements obtained from each of 798 patients who participated in the Company's Phase 2 clinical trials ASSERT, SUSTAIN and ASSURE.

4 Mar 2015

Enrollment completed in Pharma Two B's P2B001 Phase IIb study for Parkinson's disease treatment

Pharma Two B announced today that enrollment has been completed in the company's Phase IIb study of P2B001 for the treatment of early stage Parkinson's disease. One hundred and forty-nine patients enrolled in the study conducted at 29 clinical sites throughout the US and Israel.

4 Mar 2015

Drug Trial News

Existing epilepsy drug reverses aMCI in elderly patients at risk for Alzheimer's disease

Fourth patient dosed in Benitec Biopharma's Phase I/IIa hepatitis C trial

Recruitment completed for Phase III PROUD-PV trial of P1101 for treatment of polycythemia vera

Brain tumor experts launch revolutionary fast-track approach to cancer research

Chemotherapy, radiation therapy combination improves outcomes for people with low-grade brain cancer

Advanced Cell Diagnostics' RNAscope technology supports biomarker-selected phase 2 clinical trial of Merrimack Pharmaceuticals' MM-121

Pacritinib for myelofibrosis meets primary endpoint in Phase 3 PERSIST-1 trial

Clinical study launched to evaluate effectiveness of new HCV therapy in Washington, D.C.

Phase 3 trial results show that new testosterone nasal gel is effective and practical

Sunitinib holds promise for treatment of advanced differentiated thyroid cancer

Investigational drug for postmenopausal osteoporosis reduces rate of new spinal fractures

Liraglutide may help obese adults achieve weight loss

Pre-clinical data on Novogen’s Cantrixil to be presented at two upcoming conferences

Obesity drug under clinical trials could help treat anxiety

Asterias begins enrollment for AST-OPC1 Phase 1/2a trial to treat complete cervical spinal cord injury

Phase III trial to test VSV-EBOV vaccine for preventing Ebola to be launched in Guinea

Adding goserelin drug to chemotherapy prevents early menopause in young women with breast cancer

Symbiomix Therapeutics announces positive results from SYM-1219 Phase 1 clinical program

Resverlogix, Emerald Logic complete collaborative research program

Enrollment completed in Pharma Two B's P2B001 Phase IIb study for Parkinson's disease treatment

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News